Gene therapy in development for inherited vision loss

A venture-capital group which is backed by research charity giant the Wellcome Trust has invested £12m in a University of Oxford spin-out company to develop gene therapy for inherited vision loss. 

The spin-out company’s work will focus on retinal gene therapies and will test a treatment for patients with choroidermia, a rare inherited retinal condition which causes blindness. 
 
The work will build on the recent success of Professor Robert MacLaren’s group at the Nuffield Laboratory of Ophthalmology at the University of Oxford, whose clinical trials treating patients with the condition gained national press coverage. 
 
Chris Hollowood, chairman of the venture-capital group, told Bloomberg News: “Gene therapy is an extremely exciting area to be in … this is an opportunity to build an outstanding retinal therapy program.”
 
Sight loss research charity Fight for Sight has welcomed the investment, with its chief executive, Michele Acton, commenting: “It is incredibly exciting to see such significant investment being made in the development of a treatment for choroideremia and other retinal gene therapies.” 
 
More information about retinal investigation can be found here.
 
 
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply